Thelansis

Myotonic Dystrophy Type 1 (DM1) Market Outlook Thelansis’s “Myotonic Dystrophy Type 1 (DM1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myotonic Dystrophy Type 1 (DM1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

 Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults. DM1 is a dominant disorder characterized by multisystemic clinical features affecting skeletal muscle, heart, and the nervous and endocrine systems. ·        The prevalence varies by region and is most common in individuals of European descent. According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses combined prevalence reported as 1 in 8,000 (12.5 per 100,000). ·        Myotonic Dystrophy Type 1 (DM1) is caused by the expansion of a CTG repeat in the 3' noncoding region of the DMPK gene on chromosome 19q13.3, which codes for the myotonic dystrophy protein kinase. ·        Normal individuals have between 5 and 37 repeats, but symptomatic patients typically have > 50 repeats. DM1 is categorized into four subtypes: congenital, childhood, classic,...